Notably, recent data from McMahon et al. indicate that MAPK pathway activation, mainly through clonal acquisition of NRAS mutations, represents a major dynamic resistance mechanism to mutation-selective tyrosine kinase inhibitor therapy in AML [13]. This evidence concerns the gene NRAS and acute myeloid leukemia.